Scalable, sustainable and cost-effective antigen manufacturing platform for a rapid mobilisation during the current Covid-19 pandemic and possible future outbreaks

可扩展、可持续且具有成本效益的抗原制造平台，可在当前的 Covid-19 大流行和未来可能的疫情爆发期间快速动员

• 批准号: 77671
• 金额: $ 22.21万
• 依托单位: DARESBURY PROTEINS LTD.
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=77671
• 关键词: Scalable; sustainable; cost; effective; antigen

The 21st century ushered the advent of coronaviral pandemics such as SARS in 2002-2004, MERS in 2012-2018 and presently Covid-19\.These infections killed hundreds of thousands of people yet we do not know how to treat or prevent them. Our inability to identify people affected by Covid-19, has led to the spread of the infection on a global scale, causing thousands of deaths on a daily basis. Desperate lockdown measures to stop the pandemic brought many countries and vast geographical regions to a standstill. All these overwhelming effects of Covid-19 could be minimised if not completely prevented by timely and accurate ways to detect the infection.Antigen and antibody detection tests are such methods which can detect the current or past viral infection and are indispensable for the control of Covid-19 spread. However, the development and production of reliable tests require time and the availability of their key components -- viral fragments produced recombinantly. The global scale of pandemic puts a massive strain on the science and industry to supply this key component of diagnostic tests.At the time of writing, there have been 20 SARS-CoV2 antibody kits received Emergency Use Authorisation by Food and Drug Administration, FDA. None of those originated in the UK.Immense pressure on the Government to enable laboratory-based mass serological testing has hastened the adoption of the inferior quality kits sourced from abroad, the performance of which would have been found to be unacceptable in non-pandemic circumstances. Domestic industry can and must turn the tide.Daresbury Proteins will create a sustainable production platform and deploy their technology to manufacture much-needed quality antigens in the shortest timeframe to expedite the production of reliable and affordable Covid-19 testing kits. The availability of such a scalable and cost-effective platform will eliminate any issues with supply chain in the future and warrant a world-leading position of domestic diagnostic industry.

21世纪世纪迎来了冠状病毒大流行的到来，如2002-2004年的SARS，2012-2018年的MERS和目前的Covid-19。这些感染导致数十万人死亡，但我们不知道如何治疗或预防它们。我们无法识别受COVID-19影响的人，导致感染在全球范围内蔓延，每天造成数千人死亡。为阻止大流行而采取的绝望封锁措施使许多国家和广大地理区域陷入停顿。通过及时和准确的方法检测感染，即使不能完全预防，也可以将COVID-19的所有这些压倒性影响降至最低。抗原和抗体检测检测是可以检测当前或过去病毒感染的方法，对于控制COVID-19传播是不可或缺的。然而，开发和生产可靠的检测方法需要时间，而且需要获得其关键成分----重组产生的病毒片段。全球范围的大流行给科学和工业带来了巨大的压力，以提供诊断测试的这一关键组成部分。在撰写本文时，已有20个SARS-CoV 2抗体试剂盒获得了美国食品和药物管理局（FDA）的紧急使用授权。由于政府承受巨大压力，要政府推行以实验室为基础的大规模血清学测试，因此加快采用从海外采购的劣质试剂盒，而在非大流行情况下，这些试剂盒的表现是不可接受的。国内产业能够也必须扭转这一趋势。达雷斯伯里蛋白将创建一个可持续的生产平台，并部署其技术，在最短的时间内生产急需的优质抗原，以加快生产可靠和负担得起的新型冠状病毒检测试剂盒。这样一个可扩展且具有成本效益的平台的可用性将消除未来供应链的任何问题，并确保国内诊断行业的世界领先地位。